KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

NCT00646139 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Lymphoproliferative Disorder
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: Src kinase inhibitor KX2-391
OTHER: immunoenzyme technique
OTHER: pharmacological study

Sponsor

Roswell Park Cancer Institute